"Morpholines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D009025
|
MeSH Number(s) |
D03.383.533.640
|
Concept/Terms |
Morpholines- Morpholines
- Tetrahydro-1,4-Oxazines
- Tetrahydro 1,4 Oxazines
|
Below are MeSH descriptors whose meaning is more general than "Morpholines".
Below are MeSH descriptors whose meaning is more specific than "Morpholines".
This graph shows the total number of publications written about "Morpholines" by people in this website by year, and whether "Morpholines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2000 | 1 | 4 | 5 |
2001 | 0 | 2 | 2 |
2002 | 1 | 2 | 3 |
2003 | 2 | 10 | 12 |
2004 | 1 | 3 | 4 |
2005 | 0 | 6 | 6 |
2006 | 2 | 4 | 6 |
2007 | 3 | 1 | 4 |
2008 | 1 | 3 | 4 |
2009 | 1 | 4 | 5 |
2010 | 0 | 5 | 5 |
2011 | 3 | 3 | 6 |
2012 | 4 | 4 | 8 |
2013 | 1 | 6 | 7 |
2014 | 3 | 10 | 13 |
2015 | 3 | 8 | 11 |
2016 | 2 | 6 | 8 |
2017 | 4 | 4 | 8 |
2018 | 3 | 2 | 5 |
2019 | 3 | 1 | 4 |
2020 | 4 | 3 | 7 |
2021 | 4 | 5 | 9 |
2022 | 0 | 4 | 4 |
2023 | 1 | 0 | 1 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Morpholines" by people in Profiles.
-
Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control. Cell Death Dis. 2024 01 22; 15(1):80.
-
Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 Feb; 24(2):105-121.
-
Inhibiting the IRE1a Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer. Adv Sci (Weinh). 2022 07; 9(21):e2105469.
-
Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1N546K Mutation. JCO Precis Oncol. 2022 04; 6:e2100371.
-
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022 05; 33(5):522-533.
-
Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis. 2022 05; 22(5):718-730.
-
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study. Clin Lymphoma Myeloma Leuk. 2022 07; 22(7):504-512.
-
Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. J Exp Clin Cancer Res. 2021 Nov 29; 40(1):374.
-
Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Lab Invest. 2022 02; 102(2):185-193.
-
Combination of baloxavir and oseltamivir for treatment of severe influenza infection in hematopoietic cell transplant recipients: a novel treatment strategy for a high-risk population. Microbes Infect. 2022 Apr-May; 24(3):104895.